Andrada Mining acquisition elevates the miner to emerging mid-tier status. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Regulatory News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,529.50
Bid: 1,531.50
Ask: 1,532.00
Change: 3.50 (0.23%)
Spread: 0.50 (0.033%)
Open: 1,537.00
High: 1,541.50
Low: 1,523.00
Prev. Close: 1,526.00
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Director/PDMR Shareholding

12 Dec 2018 16:35

RNS Number : 3061K
GlaxoSmithKline PLC
12 December 2018
 

GlaxoSmithKline plc (the 'Company')

Transaction notification

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms E Walmsley

b)

Position/status

Chief Executive Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R G Connor

b)

Position/status

President, Global Vaccines

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr S Dingemans

b)

Position/status

Chief Financial Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr N Hirons

b)

Position/status

SVP, Global Ethics & Compliance

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr L Miels

b)

Position/status

President, Global Pharmaceuticals

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

  

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr D S Redfern

b)

Position/status

Chief Strategy Officer

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr R Simard

b)

Position/status

President, Pharma Supply Chain

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

9 (partnership shares)

£14.9439

9 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

18 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Ms C Thomas

b)

Position/status

SVP, Human Resources

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mr P C Thomson

b)

Position/status

President, Global Affairs

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

 

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

 

1.

Details of PDMR/person closely associated with them ('PCA')

a)

Name

Mrs V A Whyte

b)

Position/status

Company Secretary

c)

Initial notification/

amendment

Initial notification

2.

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

a)

Name

GlaxoSmithKline plc

b)

LEI

5493000HZTVUYLO1D793

3.

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transaction(s) has been conducted

a)

Description of the financial  instrument

Ordinary shares of 25 pence each ('Ordinary Shares')

ISIN: GB0009252882

b)

Nature of the transaction

Acquisition of Ordinary Shares under the Company's Share Reward Plan.

 

c)

Price(s) and volume(s)

Price(s)

Volume(s)

£14.9439

8 (partnership shares)

£14.9439

8 (matching shares)

 

d)

Aggregated information

 

Aggregated volume Price

 

 

 

 

16 Ordinary Shares

£14.9439

 

 

e)

Date of the transaction

2018-12-11

f)

Place of the transaction

 

London Stock Exchange (XLON)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
DSHQLLFFVLFXFBZ
Date   Source Headline
16th Oct 201711:02 amRNSDirector/PDMR Shareholding
16th Oct 201710:57 amRNSDirector/PDMR Shareholding
13th Oct 20176:31 pmRNSGSK first approval of Shingrix in Canada
13th Oct 20174:25 pmRNSDirector/PDMR Shareholding
13th Oct 20174:20 pmRNSDirector/PDMR Shareholding
13th Oct 201711:53 amRNSDirector/PDMR Shareholding
11th Oct 20171:34 pmRNSDirector/PDMR Shareholding
2nd Oct 201710:19 amRNSTotal Voting Rights
25th Sep 20172:57 pmRNSDirector/PDMR Shareholding
20th Sep 20177:00 amRNSPositive IMPACT results for Trelegy in COPD
19th Sep 20177:00 amRNSTrelegy Ellipta: FDA approval in COPD received
15th Sep 20177:00 amRNSTrelegy Ellipta: positive opinion from CHMP Europe
14th Sep 20177:00 amRNSUnanimous FDA approval for Shingrix in over 50s
12th Sep 20174:07 pmRNSDirector/PDMR Shareholding
12th Sep 20178:57 amRNSGSK: phase III results on mepo in COPD in NEJM
11th Sep 20178:08 amRNSGSK announce positive results from SLS lung study
6th Sep 20174:02 pmRNSDirector/PDMR Shareholding
10th Aug 20174:43 pmRNSDirector/PDMR Shareholding
10th Aug 201710:50 amRNSDirector/PDMR Shareholding
4th Aug 20179:06 amRNSBase prospectus re £15bn EMTN programme
1st Aug 201711:02 amRNSTotal Voting Rights
28th Jul 20174:03 pmRNSDirector/PDMR Shareholding
28th Jul 20173:51 pmRNSDirector/PDMR Shareholding
26th Jul 20171:22 pmRNSDirector/PDMR Shareholding
26th Jul 201712:41 pmRNSDirector/PDMR Shareholding - Replacement
26th Jul 201711:00 amRNSHalf-year Report
25th Jul 20171:30 pmRNSViiV announces results from NEAT 022 study
25th Jul 20171:30 pmRNSViiV announces positive results from DAWNING
24th Jul 20179:02 amRNSLATTE-2 phII results presented at IAS in Paris
21st Jul 20173:34 pmRNSDirector/PDMR Shareholding
21st Jul 20173:30 pmRNSDirector/PDMR Shareholding
21st Jul 20171:59 pmRNSGSK submits EU filing for Relvar Ellipta extension
21st Jul 201711:00 amRNSDirectorate Change
17th Jul 20176:08 pmRNSDirector/PDMR Shareholding
17th Jul 20175:44 pmRNSDirector/PDMR Shareholding
14th Jul 20174:58 pmRNSDirector/PDMR Shareholding
14th Jul 20174:46 pmRNSDirector/PDMR Shareholding
14th Jul 20174:02 pmRNSDirector/PDMR Shareholding
14th Jul 201711:57 amRNSDirector/PDMR Shareholding
12th Jul 20174:12 pmRNSDirector/PDMR Shareholding
3rd Jul 201710:05 amRNSTotal Voting Rights
28th Jun 20174:13 pmRNSGSK announces US filing for mepo in EGPA
27th Jun 201710:06 amRNSGSK starts phIII study on mepo for nasal polyps
21st Jun 20172:35 pmRNSDirector/PDMR Shareholding
21st Jun 20172:05 pmRNSGSK presents Shingrix PhIII study results at ACIP
19th Jun 20174:29 pmRNSGSK confirms start date for Luke Miels
12th Jun 20174:43 pmRNSDirector/PDMR Shareholding
5th Jun 20175:23 pmRNSDirector/PDMR Shareholding
2nd Jun 20177:00 amRNSViiV submits first 2-drug HIV regimen application
1st Jun 201710:58 amRNSTotal Voting Rights

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.